1. Tüberküloz Tanı ve Tedavi Rehberi, 2. Baskı. Sağlık Bakanlığı yayın no 1129. Ankara, Mayıs 2019.
2. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
3. Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis. 2019;
19: 903-912.
4. TB raporu Türkiye’de Verem Savaşı 2021 Raporu, T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, Yayın No: 1274, Ankara, 2023.
5. Türkiye’ye ait veriler Sağlık Bakanlığı Tüberküloz Daire Başkanlığının yayınları ve sunumlarından alınmıştır.
6. Bespiatykh D, Bespyatykh J, Mokrousov I, Shitikov E. A Comprehensive Map of Mycobacterium tuberculosis Complex Regions of Difference. mSphere. 2021; 6(4):e0053521.
7. Armstrong DT, Eisemann E, Parrish N. A Brief Update on Mycobacterial Taxonomy, 2020 to 2022. J Clin Microbiol. 2023; 61(4):e0033122.
8. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998; 393(6685): 537-44.
9. Orgeur M, Sous C, Madacki J, Brosch R. Evolution and emergence of Mycobacterium tuberculosis. FEMS Microbiol Rev. 2024; 48(2):fuae006.
10. Iseman MD. Klinisyen için Tüberküloz Kılavuzu. Çeviren: Şeref Özkara, Nobel Tıp Kitabevleri, İstanbul 2002: s. 51-62.
11. Riley RL, Mills CC, O’grady F, Sultan LU, Wıttstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different
patients. Am Rev Respir Dis. 1962; 85: 511-25.
12. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet; 353(9151): 444-9. Erratum in: Lancet 1999;
353(9165): 1714.
13. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis; 121: 939-49.
14. Iseman MD. Klinisyen için Tüberküloz Kılavuzu. Çeviren: Şeref Özkara, Nobel Tıp Kitabevleri, İstanbul 2002: s. 63-96.
15. Hopewell PC, Kato-Maeda M, Ernst JD. Tuberculosis in editor-in-chief, V. Courtney Broaddus. Murray & Nadel’s textbook of respiratory medicine, 2016. Pp. 592-628.
16. Rieder HL. Epidemiologic Basis of Tuberculosis Control. International Union Against Tuberculosis and Lung Disease, First Edition, 1999, p. 63-66.
17. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974 Feb;99(2):131-8. doi: 10.1093/oxfordjournals.
aje.a121593. PMID: 4810628.
18. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune
Defic Syndr; 23: 75-80.
19. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the
community. PLoS One. 2012; 7(3): e34156.
20. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010; 36: 1185-206.
21. Grzybowski S, Fishaut H, Rowe J, Brown A. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis 1971; 104: 605-8.
22. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial.
International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982; 60: 555-64.
23. https-who tr https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=”country”&iso2=”TR”&lan=”EN” (28.5.2024 tarihinde ulaşıldı.)
24. Frascella B, Richards AS, Sossen B, et al. Subclinical tuberculosis disease-a review and analysis of prevalence surveys to ınform definitions, burden, associations, and screening methodology.
Clin Infect Dis. 2021; 73(3): e830-e841.
25. Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana RR, Zwerling AA, Denkinger CM, Steingart KR, Shah M. Lateral flow urine lipoarabinomannan assay for detecting active tuber-
culosis in people living with HIV. Cochrane Database Syst Rev. 2019 Oct 21;10(10):CD011420. doi: 10.1002/14651858.CD011420.pub3. PMID: 31633805; PMCID: PMC6802713.
26. Dorman SE, Nahid P, Kurbatova EV, et al. Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021; 384: 1705-
1718.
27. Nyang’wa BT, Berry C, Kazounis E, et al.; TB-PRACTECAL Study Collaborators. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022; 387: 2331-2343.
28. Iseman MD. Klinisyen için Tüberküloz Kılavuzu. Çeviren: Şeref Özkara, Nobel Tıp Kitabevleri, İstanbul 2002: s. 271-323.
29. Prasad K, Volmink J, Menon GR. Steroids for treating tuberculous meningitis. Cochrane Database Syst Rev. 2007;(1):CD002244.
30. Wyser C, Walzl G, Smedema JP, Swart F, van Schalkwyk EM, van de Wal BW. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study.
Chest. 1996; 110: 333-8.
31. Elliott AM, Luzze H, Quigley MA, et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis.
J Infect Dis. 2004; 190: 869-78.
32. Mayosi BM, Ntsekhe M, Bosch J, et al.; IMPI Trial Investigators. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014; 371: 1121-30.
33. Buhari GK, Keren M, Dursun AB, Güler M, Dulkar G, Kalaç N, Özkara S, Erkekol FÖ. Immediate-type hypersensitivity reactions due to antituberculosis drugs: a successful readministration
protocol. Ann Allergy Asthma Immunol. 2015; 115: 39-44.
34. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO
35. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
36. World Health Organization. Tuberculosis preventive treatment, Rapid Communication, 2024
37. Jensen PA, Lambert LA, Iademarco MF. Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005. Morbidity and Mortality Weekly Report
(MMWR). 2005 / 54(No.RR17);1-141
38. WHO guidelines on tuberculosis infection prevention and control, 2019 update, Geneva: World Health Organization; 2019. License: CC BY-NC-SA 3.0 IGO.
39. Tuberculosis and air travel : guidelines for prevention and control – 3rd ed, 2008. “WHO/HTM/TB/2008.399”
40. The End TB Strategy. 2015. “WHO/HTM/TB/2015.19”